1. Wijdicks EF. Hepatic Encephalopathy. N Engl J Med. 2016;375(17):1660-1670. Doi:10.1056/NEJMra1600561.
2. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50(6):201421. Doi: 10.1002/hep.23216
3. Mandiga P, Kommu S, Bollu PC. Hepatic Encephalopathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.
4. Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis. 2012;16(2):30120. Doi: 10.1016/j.cld.2012.03.009.
5. Sharma P. Minimal hepatic encephalopathy. J Assoc Physicians India. 2009 Nov;57:7603.
6. Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2048-61. doi: 10.1016/j.cgh.2015.06.039.
7. Hoilat GJ, Suhail FK, Adhami T, John S. Evidence-based approach to management of hepatic encephalopathy in adults. World J Hepatol 2022; 14(4): 670-681. DOI: https://dx.doi.org/10.4254/wjh.v14.i4.670
8. Ridola L. Hepatic encephalopathy in adults: Treatment. UpToDate. 2024. https://www.uptodate.com/contents/hepatic-encephalopathy-in-adults-treatment
9. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 ;60(2):715-35. Doi: 10.1002/hep.27210.
10. Cordoba J, Lopez-hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43. Doi:10.1016/j.jhep.2004.03.023.
11. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31(5):537-47. Doi: 10.1111/j.1365-2036.2009.04211.x.
12. Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58(1):325.-36. Doi:10.1002/hep.26370.
13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J. Hepatol.2022;77(3):807. Doi: 101016/j.jhep.2022.06.001
14. Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28(2):313-20. Doi: 10.1007/s11011-013-9392-4.
15. Mukherjee S, John S. Lactulose. 2021 Jul 19. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
16. Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol hepatol.2014;12(8):1390-7.e2. doi: 10.1016/j.cgh.2013.12.021.
17. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol. 2020;26(2):83127.
18. Zhu GQ, Shi KQ, Huang S, et al. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther.2015;41(7):624-35. Doi: 10.1111/apt.13122.
19. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J hepatol. 1993;19(3):424-30. Doi: 10.1016/s0168-8278(05)80553-7.
20. Bai M, he C, Yin Z, et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther.2014;40(1):63-71. Doi: 10.1111/apt.12795.
21. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine-L-aspartate in acute liver failure: a double blind, randomized, placebo-controlled study. Gastroenterology. 2009;136(7):2159-68. Doi: 10,1053/j.gastro.2009.02.050.
22. Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev.2017;5(5):CD001939. Doi: 10.1002/14651858.CD001939.pub4.
23. Les I, Doval E, Garcia-martinez R, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106(6):1081-8. Doi: 10.1038/ajg.2011.9.
24. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174(11):1727-33. Doi: 10.1001/jamainternmed.2014.4746.
25. Hoilat GJ, Ayas MF, Hoilat JN, AbuZaid A, Durer C, Durer S, Adhami T, John S. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and metaanalysis. BMJ Open Gastroenterol. 2021;8(1):e000648. Doi: 10.1136/bmjgast-2021-000648.
26. Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2(2):CD008716. Doi: 10.1002/14651858.CD008716.pub3.
27. Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil vs placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;8:CD002798. DOI: 10.1002/14651858.CD002798.pub4
28. Katayama K, Kawaguchi T, Shiraishi K, et al. The Prevalence and Implication of Zinc Deficiency in Patients With Chronic Liver Disease. J Clin Med Res 2018;10:437-444. DOI: 10.14740/jocmr3374w
29. Rahelić D, Kujundzić M, Romić Z, Brkić K, Petrovecki M. Serum concentration of zinc, copper, manganese and magnesium in patients with liver cirrhosis. Coll Antropol. 2006;30:523-528.
30. Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutiérrez T, Villegas-López FA, Méndez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J. 2013;12:74. DOI: 10.1186/1475-2891-12-74
31. Shen YC, Chang YH, Fang CJ, Lin YS. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J. 2019;18:34. DOI: 10.1186/s12937-019-0461-3
32. Laleman W, Simon-Talero M, Maleux G, et al; EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57:2448-2457. DOI: 10.1002/hep.26314
33. Lynn AM, Singh S, Congly SE, Khemani D, Johnson DH, Wiesner RH, Kamath PS, Andrews JC, Leise MD. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transpl. 2016;22:723-731.
34. Frederick RT. Extent of reversibility of hepatic encephalopathy following liver transplantation. Clin Liver Dis. 2012;16:147-158, DOI: 10.1016/j.cld.2011.12.004